

## Anti-IL-10R [1B1.3a] VivopureX 50 mg Ab01490-2.3-VXF

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric mouse antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Mouse IgG2a, [Fc Silent™](#), Kappa

**Clone Number:** 1B1.3a

**Alternative Name(s) of Target:** CD210; Interleukin-10 receptor subunit; Interleukin-10 receptor subunit alpha; IL10ra IL10r; IL-10 receptor subunit alpha; IL-10R subunit alpha; IL-10RA; CDw210a; Interleukin-10 receptor subunit 1; IL-10R subunit 1; IL-10R1; IBI-3A; 1B1-3A

**UniProt Accession Number of Target Protein:** Q61727

**Published Application(s):** Blocking, FC

**Published Species Reactivity:** Mouse

**Immunogen:** This antibody was raised by immunising rats with the purified recombinant extracellular region of mouse Interleukin 10 Receptor.

**Specificity:** This antibody recognises mouse IL-10R which is a cell surface glycoprotein and a receptor for anti-inflammatory IL-10. The epitope recognised by this antibody has been localised to the ligand binding domain within the extracellular region of mouse IL-10R.

**Application Notes:** 1B1.3a has been widely applied in flow cytometric analyses where the detection of IL-10R was needed. Furthermore, this antibody was also successfully utilised as a blocking agent; one group used it to demonstrate that IL-10 mediates suppressive activity, by targeting its receptor IL-10R with this antibody (Wang et al., 2004). Castro et al. (2000) demonstrated that 1B1.3a is able to make a soluble peptide or protein antigen immunogenic for subsequent Th1 recall responses in a situation when there is an additional signal, such as LPS, activating the immune system. Consequently, this antibody is a hugely promising agent in the potential development of vaccines for immunotherapy. Similarly, Vicari and colleagues (2002) showed that this antibody has an enormous potential as a therapeutic anti-tumour agent when combined with the administration of CpG to stimulate the immune system.

**Antibody First Published in:** O'Farrell et al. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J. 1998 Feb 16;17(4):1006-18. [PMID:9463379](#)

**Note on publication:** This article describes the method of generation of antibodies like 1B1.3a.

## Product Form

**Size:** 50 mg VivopureX products are produced at high purity (>98%), low endotoxin (<0.5 EU/mg) and are formulated without preservatives. These antibodies are chimerized to have an Fc domain matching their target species to reduce immunogenicity and give you the optimal effector function for your experiment. As a result VivopureX products are the ideal choice for in vivo research applications.

**Purification:** Protein A affinity purified

**Supplied In:** PBS only.

**Storage Recommendation:** All VivopureX products are formulated in PBS only without addition of preservatives. To ensure optimal storage and prevent microbial contamination, only open and dispense

under sterile conditions.

**Concentration:**  $\geq 1\text{mg}$  (see vial label for exact conc)

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.